Early Versus Conventional Cessation of Hydrocortisone in Septic Shock

Launched by MAHIDOL UNIVERSITY · Apr 18, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how to safely stop using hydrocortisone, a steroid medication, in patients who are recovering from septic shock. Septic shock is a serious condition that can happen when the body has a severe infection, leading to low blood pressure and potential organ failure. The trial aims to compare two different approaches: stopping hydrocortisone early versus using it for a longer time during recovery. This research is important because finding the best way to manage hydrocortisone can help improve patient outcomes and reduce complications.

To be eligible for this trial, participants must be at least 18 years old and diagnosed with septic shock, having received certain medications, including hydrocortisone. Participants should also be able to maintain a stable blood pressure with lower doses of other medications. Those who are pregnant, terminally ill, or need long-term steroid treatment for other health issues cannot participate. If chosen for the trial, participants will be closely monitored to see how well they respond to the different ways of stopping hydrocortisone, helping doctors learn more about the best practices for treating septic shock.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient \>= 18 years old
• • Diagnosis Septic shock from the definition of SEPSIS III criteria in intensive care unit or medicine ward or surgical ward at Siriraj hospital
• • Received at least 1 catecholamines and hydrocortisone at least 200 mg/d
• • Maintain mean arterial pressure \>= 65 mmHg even if titrate down catecholamines until low dose (\<=0.1 mcg/kg/min)
• Exclusion Criteria:
• • Patient sign Do not resuscitation and terminally ill
• • Pregnancy
• • Need long term steroid use due to other medical condition